Younss Ait Mou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Younss Ait Mou has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
Pieter P. de Tombe
Department of Cell and Molecular Physiology, Heath Science Division, Loyola University Chicago, Maywood, IL 60153, USA
7 shared publications- Alain Lacampagne
PhyMedExp, University of Montpellier, INSERM, CNRS
5 shared publications Thomas C. Irving
Department of Biological and Chemical Sciences, Illinois Institute of Technology, Chicago, IL 60616
4 shared publications- Amina Daoud
Hamad Bin Khalifa University
3 shared publications - Devi G. Kurup
Hamad Bin Khalifa University
3 shared publications - Hamada R. H. Al-Absi
Hamad Bin Khalifa University
3 shared publications
Latest Publications
- 1 October 2025
- Published by Springer Nature
- p. 343-352
Geo-spatial and Temporal Analysis of Hadith Narrators
- 1 October 2025
- Published by Springer Nature
- p. 343-352
Geo-spatial and Temporal Analysis of Hadith Narrators
- 2 February 2025
- Published by Springer Nature
- p. 127-138
Exploring Semantic Hadith Overlap Across Topics
- 2 February 2025
- Published by Springer Nature
- p. 127-138
Exploring Semantic Hadith Overlap Across Topics
- 1 June 2024
- Published by Springer Nature
- p. 3-8
Al-Ahadeeth: A Visualization Tool of the Hadiths’ Chain of Narrators
- 1 June 2024
- Published by Springer Nature
- p. 3-8
Al-Ahadeeth: A Visualization Tool of the Hadiths’ Chain of Narrators
- 1 January 2018
- Published by Elsevier in Journal of Molecular and Cellular Cardiology
- Vol. 114, 345-353
Altered myofilament structure and function in dogs with Duchenne muscular dystrophy cardiomyopathy
- 1 January 2018
- Published by Elsevier in Journal of Molecular and Cellular Cardiology
- Vol. 114, 345-353
Altered myofilament structure and function in dogs with Duchenne muscular dystrophy cardiomyopathy
- 8 February 2016
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 113 (8) , 2306-2311
Titin strain contributes to the Frank–Starling law of the heart by structural rearrangements of both thin- and thick-filament proteins
The Frank–Starling mechanism of the heart is due, in part, to modulation of myofilament Ca2+ sensitivity by sarcomere length (SL) [length-dependent activation (LDA)]. The molecular mechanism(s) that underlie LDA are unknown. Recent evidence has implicated the giant protein titin in this cellular process, possibly by positioning the myosin head closer to actin. To clarify the role of titin strain in LDA, we isolated myocardium from either WT or homozygous mutant (HM) rats that express a giant splice isoform of titin, and subjected the muscles to stretch from 2.0 to 2.4 μm of SL. Upon stretch, HM compared with WT muscles displayed reduced passive force, twitch force, and myofilament LDA. Time-resolved small-angle X-ray diffraction measurements of WT twitching muscles during diastole revealed stretch-induced increases in the intensity of myosin (M2 and M6) and troponin (Tn3) reflections, as well as a reduction in cross-bridge radial spacing. Independent fluorescent probe analyses in relaxed permeabilized myocytes corroborated these findings. X-ray electron density reconstruction revealed increased mass/ordering in both thick and thin filaments. The SL-dependent changes in structure observed in WT myocardium were absent in HM myocardium. Overall, our results reveal a correlation between titin strain and the Frank–Starling mechanism. The molecular basis underlying this phenomenon appears not to involve interfilament spacing or movement of myosin toward actin but, rather, sarcomere stretch-induced simultaneous structural rearrangements within both thin and thick filaments that correlate with titin strain and myofilament LDA. Significance The Frank–Starling law of the heart represents a fundamental regulatory mechanism whereby cardiac pump performance is directly modulated by the extent of diastolic ventricular filling on a beat-to-beat basis. It is now well established that sarcomere length (SL)-induced changes in cardiac contractile protein responsiveness to activating calcium ions play a major role in this phenomenon. However, the molecular mechanisms that underlie this SL-sensing property are not known. Here, we show by small-angle X-ray diffraction and fluorescent probe techniques that the giant protein titin likely transmits the length signal to induce structural alterations in both thin- and thick-filament contractile proteins. These findings provide insights into the molecular basis of the Frank–Starling regulatory mechanism.
- 8 February 2016
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 113 (8) , 2306-2311
Titin strain contributes to the Frank–Starling law of the heart by structural rearrangements of both thin- and thick-filament proteins
The Frank–Starling mechanism of the heart is due, in part, to modulation of myofilament Ca2+ sensitivity by sarcomere length (SL) [length-dependent activation (LDA)]. The molecular mechanism(s) that underlie LDA are unknown. Recent evidence has implicated the giant protein titin in this cellular process, possibly by positioning the myosin head closer to actin. To clarify the role of titin strain in LDA, we isolated myocardium from either WT or homozygous mutant (HM) rats that express a giant splice isoform of titin, and subjected the muscles to stretch from 2.0 to 2.4 μm of SL. Upon stretch, HM compared with WT muscles displayed reduced passive force, twitch force, and myofilament LDA. Time-resolved small-angle X-ray diffraction measurements of WT twitching muscles during diastole revealed stretch-induced increases in the intensity of myosin (M2 and M6) and troponin (Tn3) reflections, as well as a reduction in cross-bridge radial spacing. Independent fluorescent probe analyses in relaxed permeabilized myocytes corroborated these findings. X-ray electron density reconstruction revealed increased mass/ordering in both thick and thin filaments. The SL-dependent changes in structure observed in WT myocardium were absent in HM myocardium. Overall, our results reveal a correlation between titin strain and the Frank–Starling mechanism. The molecular basis underlying this phenomenon appears not to involve interfilament spacing or movement of myosin toward actin but, rather, sarcomere stretch-induced simultaneous structural rearrangements within both thin and thick filaments that correlate with titin strain and myofilament LDA. Significance The Frank–Starling law of the heart represents a fundamental regulatory mechanism whereby cardiac pump performance is directly modulated by the extent of diastolic ventricular filling on a beat-to-beat basis. It is now well established that sarcomere length (SL)-induced changes in cardiac contractile protein responsiveness to activating calcium ions play a major role in this phenomenon. However, the molecular mechanisms that underlie this SL-sensing property are not known. Here, we show by small-angle X-ray diffraction and fluorescent probe techniques that the giant protein titin likely transmits the length signal to induce structural alterations in both thin- and thick-filament contractile proteins. These findings provide insights into the molecular basis of the Frank–Starling regulatory mechanism.
- Open Access
- 1 January 2015
- Published by Global Cardiology Science and Practice in Global Cardiology Science and Practice
- Vol. 2015 (1) , 10
Exploring cardiac biophysical properties
The heart is subject to multiple sources of stress. To maintain its normal function, and successfully overcome these stresses, heart muscle is equipped with fine-tuned regulatory mechanisms. Some of these mechanisms are inherent within the myocardium itself and are known as intrinsic mechanisms. Over a century ago, Otto Frank and Ernest Starling described an intrinsic mechanism by which the heart, even ex vivo, regulates its function on a beat-to-beat basis. According to this phenomenon, the higher the ventricular filling is, the bigger the stroke volume. Thus, the Frank-Starling law establishes a direct relationship between the diastolic and systolic function of the heart. To observe this biophysical phenomenon and to investigate it, technologic development has been a pre-requisite to scientific knowledge. It allowed for example to observe, at the cellular level, a Frank-Starling like mechanism and has been termed: Length Dependent Activation (LDA). In this review, we summarize some experimental systems that have been developed and are currently still in use to investigate cardiac biophysical properties from the whole heart down to the single myofibril. As a scientific support, investigation of the Frank-Starling mechanism will be used as a case study.
- 1 January 2015
- Published by Global Cardiology Science and Practice in Global Cardiology Science and Practice
- Vol. 2015 (1) , 10
Open AccessExploring cardiac biophysical properties
The heart is subject to multiple sources of stress. To maintain its normal function, and successfully overcome these stresses, heart muscle is equipped with fine-tuned regulatory mechanisms. Some of these mechanisms are inherent within the myocardium itself and are known as intrinsic mechanisms. Over a century ago, Otto Frank and Ernest Starling described an intrinsic mechanism by which the heart, even ex vivo, regulates its function on a beat-to-beat basis. According to this phenomenon, the higher the ventricular filling is, the bigger the stroke volume. Thus, the Frank-Starling law establishes a direct relationship between the diastolic and systolic function of the heart. To observe this biophysical phenomenon and to investigate it, technologic development has been a pre-requisite to scientific knowledge. It allowed for example to observe, at the cellular level, a Frank-Starling like mechanism and has been termed: Length Dependent Activation (LDA). In this review, we summarize some experimental systems that have been developed and are currently still in use to investigate cardiac biophysical properties from the whole heart down to the single myofibril. As a scientific support, investigation of the Frank-Starling mechanism will be used as a case study.
- Open Access
- 1 April 2014
- Published by Wiley in The FASEB Journal
- Vol. 28 (S1) , 1081.5
Protein kinase C‐site phosphorylation of cardiac myosin binding protein‐C decreases cross‐bridge kinetics (1081.5)
Cardiac myosin binding protein‐C (cMyBP‐C) phosphorylation is necessary for the regulation of sarcomeric structure and myocardial contractility in vivo. Different from skeletal isoforms, cMyBP‐C has M‐domain phosphorylation motifs in which three serines, Ser273, 282 and 302, are known to be substrates for several kinases. Phosphorylation of these M‐domain sites regulates the interaction of cMyBP‐C with thick and thin myofilaments during muscle contraction. While protein kinase C (PKC) is known to phosphorylate Ser273 and Ser302, the precise functional consequences of PKC‐mediated cMyBP‐C phosphorylation are not fully characterized. Therefore, the objective of this study was to determine how PKC‐mediated phosphorylation at Ser273/302 might control the function of cMyBP‐C in the context of thick and thin myofilament regulation and sarcomere contraction. Using recombinant proteins and yeast‐2‐hybrid (Y2H) clones expressing Ser273‐Ser282‐Ser302 (cMyBP‐CWT), Ala273‐Asp282‐Ala302 (cMyBP‐CADA) or Asp273‐Ala282‐Asp302 (cMyBP‐CDAD), cosedimentation of C0C2 and Y2H of C1C2 assays with either cardiac myosin S2 region or sarcomeric actin revealed that PKC phosphorylation of Ser273/Ser302 in cMyBP‐C M‐domain is sufficient to maintain its interaction with myosin S2 region, but diminish its interaction with actin in vitro. Furthermore, mechanical studies using skinned ventricular fibers from cMyBP‐CDAD revealed that PKC phospho‐mimetic exhibits a significant decrease in active force, cross‐bridge kinetics and Mg2+‐ATPase activity and myofilament Ca2+ sensitivity in vitro, compared to the controls. Taken together, our studies demonstrated that two phosphorylatable (by PKC) serines in cMyBP‐C M‐domain enable the interaction between cMyBP‐C protein and myosin S2, but diminishes its interaction with actin, thus affecting the ability of this protein to regulate sarcomere contractility
- 1 April 2014
- Published by Wiley in The FASEB Journal
- Vol. 28 (S1) , 1081.5
Open AccessProtein kinase C‐site phosphorylation of cardiac myosin binding protein‐C decreases cross‐bridge kinetics (1081.5)
Cardiac myosin binding protein‐C (cMyBP‐C) phosphorylation is necessary for the regulation of sarcomeric structure and myocardial contractility in vivo. Different from skeletal isoforms, cMyBP‐C has M‐domain phosphorylation motifs in which three serines, Ser273, 282 and 302, are known to be substrates for several kinases. Phosphorylation of these M‐domain sites regulates the interaction of cMyBP‐C with thick and thin myofilaments during muscle contraction. While protein kinase C (PKC) is known to phosphorylate Ser273 and Ser302, the precise functional consequences of PKC‐mediated cMyBP‐C phosphorylation are not fully characterized. Therefore, the objective of this study was to determine how PKC‐mediated phosphorylation at Ser273/302 might control the function of cMyBP‐C in the context of thick and thin myofilament regulation and sarcomere contraction. Using recombinant proteins and yeast‐2‐hybrid (Y2H) clones expressing Ser273‐Ser282‐Ser302 (cMyBP‐CWT), Ala273‐Asp282‐Ala302 (cMyBP‐CADA) or Asp273‐Ala282‐Asp302 (cMyBP‐CDAD), cosedimentation of C0C2 and Y2H of C1C2 assays with either cardiac myosin S2 region or sarcomeric actin revealed that PKC phosphorylation of Ser273/Ser302 in cMyBP‐C M‐domain is sufficient to maintain its interaction with myosin S2 region, but diminish its interaction with actin in vitro. Furthermore, mechanical studies using skinned ventricular fibers from cMyBP‐CDAD revealed that PKC phospho‐mimetic exhibits a significant decrease in active force, cross‐bridge kinetics and Mg2+‐ATPase activity and myofilament Ca2+ sensitivity in vitro, compared to the controls. Taken together, our studies demonstrated that two phosphorylatable (by PKC) serines in cMyBP‐C M‐domain enable the interaction between cMyBP‐C protein and myosin S2, but diminishes its interaction with actin, thus affecting the ability of this protein to regulate sarcomere contractility
- 1 January 2014
- Published by Elsevier in Biophysical Journal
- Vol. 106 (2) , 161a-161A
Titin-Based Modulation of Sarcomere Structure as Revealed by Equatorial X-Ray Diffraction
- 1 January 2014
- Published by Elsevier in Biophysical Journal
- Vol. 106 (2) , 161a-161A
Titin-Based Modulation of Sarcomere Structure as Revealed by Equatorial X-Ray Diffraction
- 1 January 2013
- Published by Elsevier in Biophysical Journal
- Vol. 104 (2) , 453a
Cardiac Thin Filament Activation Modulation by Stretch
- 1 January 2013
- Published by Elsevier in Biophysical Journal
- Vol. 104 (2) , 453a
Cardiac Thin Filament Activation Modulation by Stretch
- Open Access
- 4 May 2012
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 95 (1) , 86-96
Bradykinin restores left ventricular function, sarcomeric protein phosphorylation, and e/nNOS levels in dogs with Duchenne muscular dystrophy cardiomyopathy
Cardiomyopathy is a lethal result of Duchenne muscular dystrophy (DMD), but its characteristics remain elusive. The golden retriever muscular dystrophy (GRMD) dogs produce DMD pathology and mirror DMD patient's symptoms, including cardiomyopathy. We previously showed that bradykinin slows the development of pacing-induced heart failure. Therefore, the goals of this research were to characterize dystrophin-deficiency cardiomyopathy and to examine cardiac effects of bradykinin in GRMD dogs. At baseline, adult GRMD dogs had reduced fractional shortening (28 ± 2 vs. 38 ± 2% in control dogs, P < 0.001) and left ventricular (LV) subendocardial dysfunction leading to impaired endo-epicardial gradient of radial systolic velocity (1.3 ± 0.1 vs. 3.8 ± 0.2 cm/s in control dogs, P < 0.001) measured by echocardiography. These changes were normalized by bradykinin infusion (1 µg/min, 4 weeks). In isolated permeabilized LV subendocardial cells of GRMD dogs, tension–calcium relationships were shifted downward and force-generating capacity and transmural gradient of myofilament length-dependent activation were impaired compared with control dogs. Concomitantly, phosphorylation of sarcomeric regulatory proteins and levels of endothelial and neuronal nitric oxide synthase (e/nNOS) in LV myocardium were significantly altered in GRMD dogs. All these abnormalities were normalized in bradykinin-treated GRMD dogs. Cardiomyopathy in GRMD dogs is characterized by profound LV subendocardial dysfunction, abnormal sarcomeric protein phosphorylation, and impaired e/nNOS, which can be normalized by bradykinin treatment. These data provide new insights into the pathophysiological mechanisms accounting for DMD cardiomyopathy and open new therapeutic perspectives.
- 4 May 2012
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 95 (1) , 86-96
Open AccessBradykinin restores left ventricular function, sarcomeric protein phosphorylation, and e/nNOS levels in dogs with Duchenne muscular dystrophy cardiomyopathy
Cardiomyopathy is a lethal result of Duchenne muscular dystrophy (DMD), but its characteristics remain elusive. The golden retriever muscular dystrophy (GRMD) dogs produce DMD pathology and mirror DMD patient's symptoms, including cardiomyopathy. We previously showed that bradykinin slows the development of pacing-induced heart failure. Therefore, the goals of this research were to characterize dystrophin-deficiency cardiomyopathy and to examine cardiac effects of bradykinin in GRMD dogs. At baseline, adult GRMD dogs had reduced fractional shortening (28 ± 2 vs. 38 ± 2% in control dogs, P < 0.001) and left ventricular (LV) subendocardial dysfunction leading to impaired endo-epicardial gradient of radial systolic velocity (1.3 ± 0.1 vs. 3.8 ± 0.2 cm/s in control dogs, P < 0.001) measured by echocardiography. These changes were normalized by bradykinin infusion (1 µg/min, 4 weeks). In isolated permeabilized LV subendocardial cells of GRMD dogs, tension–calcium relationships were shifted downward and force-generating capacity and transmural gradient of myofilament length-dependent activation were impaired compared with control dogs. Concomitantly, phosphorylation of sarcomeric regulatory proteins and levels of endothelial and neuronal nitric oxide synthase (e/nNOS) in LV myocardium were significantly altered in GRMD dogs. All these abnormalities were normalized in bradykinin-treated GRMD dogs. Cardiomyopathy in GRMD dogs is characterized by profound LV subendocardial dysfunction, abnormal sarcomeric protein phosphorylation, and impaired e/nNOS, which can be normalized by bradykinin treatment. These data provide new insights into the pathophysiological mechanisms accounting for DMD cardiomyopathy and open new therapeutic perspectives.